drugset / Trial / NCT01150812
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects
NaSingle-groupOpen-label
Summary
The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single oral low doses.
Timeline
- Start
- 2010-06
- Primary completion
- 2010-08
- Completion
- 2010-08
Outcome
Outcome not reported
Stopped: “The study pharmacodynamic stopping criteria were met after the first dosing group”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD8165 | Small molecule | 2 mg/ml | Oral |
| Subject | AZD8165 | Small molecule | 20 mg/ml | Oral |
Indications
No indication recorded.